Aldeyra Therapeutics/$ALDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Ticker
$ALDX
Sector
Primary listing
Employees
8
Headquarters
Website
ALDX Metrics
BasicAdvanced
$306M
-
-$0.85
0.75
-
Price and volume
Market cap
$306M
Beta
0.75
52-week high
$7.20
52-week low
$1.14
Average daily volume
846K
Financial strength
Current ratio
2.863
Quick ratio
2.774
Long term debt to equity
0.259
Total debt to equity
28.136
Interest coverage (TTM)
-28.00%
Profitability
EBITDA (TTM)
-53.061
Management effectiveness
Return on assets (TTM)
-31.58%
Return on equity (TTM)
-65.91%
Valuation
Price to book
5.53
Price to tangible book (TTM)
5.53
Price to free cash flow (TTM)
-7.412
Free cash flow yield (TTM)
-13.49%
Free cash flow per share (TTM)
-0.687
Growth
Earnings per share change (TTM)
32.53%
3-year earnings per share growth (CAGR)
-9.32%
10-year earnings per share growth (CAGR)
-4.51%
What the Analysts think about ALDX
Analyst ratings (Buy, Hold, Sell) for Aldeyra Therapeutics stock.
Bulls say / Bears say
Despite the FDA’s second complete response letter, Aldeyra is continuing two ongoing pivotal reproxalap trials and plans to resubmit its NDA later this year, underscoring a resilient development strategy (Reuters)
Aldeyra’s exclusive option agreement with AbbVie for reproxalap provides a potential $94 million upfront payment and co-development option, offering a crucial non-dilutive funding pathway upon approval (Reuters)
Dry eye disease affects approximately 16.4 million Americans, indicating a sizeable addressable market and multibillion-dollar commercial opportunity for reproxalap if approved (Reuters)
The FDA’s complete response letter marked the second rejection for reproxalap, citing failure to demonstrate efficacy and requiring at least one additional adequate trial, significantly delaying the approval timeline (Reuters)
A late-stage trial involving 132 patients failed to sufficiently prove reproxalap’s efficacy in reducing ocular discomfort, raising questions about the consistency of its clinical data (Reuters)
Following the FDA’s complete response letter, Aldeyra’s shares plunged 73% in premarket trading, reflecting pronounced investor skepticism and high downside risk in the equity (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
ALDX Financial Performance
Revenues and expenses
ALDX Earnings Performance
Company profitability
ALDX News
AllArticlesVideos
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Business Wire2 weeks ago
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
Business Wire3 weeks ago
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aldeyra Therapeutics stock?
Aldeyra Therapeutics (ALDX) has a market cap of $306M as of September 16, 2025.
What is the P/E ratio for Aldeyra Therapeutics stock?
The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of September 16, 2025.
Does Aldeyra Therapeutics stock pay dividends?
No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Aldeyra Therapeutics dividend payment date?
Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Aldeyra Therapeutics?
Aldeyra Therapeutics (ALDX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.